Skip to content

Smartwatch Paroxysmal Arrhythmia Detection Compared with Holter

Smartwatch Paroxysmal Arrhythmia Detection Compared with Holter - a Multicenter Controlled Trial

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06425887
Enrollment
185
Registered
2024-05-23
Start date
2024-07-01
Completion date
2026-07-01
Last updated
2024-10-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Arrythmia

Brief summary

The lifetime risk for development of atrial fibrillation, the commonest sustained arrhythmia in adults, is estimated to be 24%-27% for individuals of 40 years or older. Previous work showed that annual new diagnosis of AF is 11000-26000 in Hong Kong. Other arrhythmia such as supraventricular arrhythmia or premature beats were also common and of clinical significance. 12-lead ECG is a first line investigation for patients with suspected paroxysmal arrhythmia, but it has a low diagnostic yield with its 10-30 seconds recordings. 24-hour Holter exam is the usual next step of diagnosis. The diagnostic yield of Holter varies according to indication but is generally low at 1%-12%. This is because paroxysmal arrhythmia may not happen every day. In addition, even if arrhythmia is picked up in Holter, patient may not register the symptom, making the symptom arrhythmia correlation problematic. Despite limitations, the demand for Holter exam is still high. In Prince of Wales Hospital, a tertiary referral centre with a catchment of about 1 million populations, the waiting time for a routine Holter exam is 3 years. Smartwatch has gained popularity over past years as an adjunct to smartphone. Latest generations of smartwatch were equipped with wearer-initiated ECG rhythm strip recording capabilities. Smartwatch has evolved to become a health tracker with arrhythmia detection capabilities. It was found to be a useful tool for atrial fibrillation screening in general population. Other arrhythmias, such as supraventricular tachycardia, premature beats, and abnormal ECG patterns associated with sudden cardiac death could also be detected with smartwatch ECG recordings. Apple Heart study was the largest study utilizing smartwatch for arrhythmia detection. The general population was screened for atrial fibrillation using irregular pulse algorithm. The study found a 84% concordance rate between irregular pulse notification and ECG patches. Therefore, investigators propose to conduct a study to compare its diagnostic yield with Holter, in patients with suspected arrhythmia and see if smartwatch recording following a systematic protocol for four-weeks will have better arrhythmia diagnosis yield than a 24-hour Holter exam.

Interventions

DIAGNOSTIC_TESTSmart watch

not interventional

Sponsors

Chinese University of Hong Kong
Lead SponsorOTHER

Study design

Observational model
OTHER
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

1. All patients referred for out-patient Holter exam from age 18 - 80 years old 2. The following indications for Holter exam will be allowed for recruitment * Palpitation * Pre-syncope * Dizziness

Exclusion criteria

1. Patients with a prior ECG diagnosis to explain the symptom 2. Primary symptom is syncope 3. Patient who has no clear indication for Holter exam 4. Pregnant ladies 5. Patients who failed to make a successful recording despite teaching attempts. 6. Patients who cannot read English or Chinese version of consent. 7. Anticipation of non-compliance with recording protocol. 8. Patients who do not have a compatible smart phone (Android 9.0 or newer, or iOS15 or newer) 9. Patients under custody

Design outcomes

Primary

MeasureTime frameDescription
Comparisonthrough study completion, an average of 1 monthCompare the percentage of patients with significant arrhythmia diagnosed, between smartwatch rhythm recording and 24-hour Holter arm Significant arrhythmia is defined as the presence of any one of the following * Sustained supraventricular tachycardia (\>=30 seconds) * Atrial fibrillation (\>=30 seconds) * Ventricular tachycardia of more than 3 consecutive beats * Significant AV block (defined as 2nd degree Mobitz type II or 3rd degree heart block) * HR less than 40 while awake. * Pause \> 2 seconds while awake (for both smartwatch and Holter), or \>3 seconds while asleep (for Holter only) * Premature ventricular complex with an overall burden of more than 10%

Secondary

MeasureTime frameDescription
Detection ratethrough study completion, an average of 1 monthdescribe the detection rate of smartwatch for various arrhythmia
Preferencethrough study completion, an average of 1 monthdescribe patients' preference on using which modality (smartwatch or Holter) to record their arrhythmia, by means of a questionnaire

Countries

Hong Kong

Contacts

Primary ContactTsz Kin Mark Tam
marktam@cuhk.edu.hk852 35051750

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026